Rafiq Hasan, Complement Therapeutics CEO
April 17, 2023 01:30 AM EDT
Financing
Startups
Cell/Gene Tx

VCs 'Com­ple­men­t' Eu­ro­pean biotech with $79M for reti­nal AAV gene ther­a­py tri­al next year

Kyle LaHucik

Senior Reporter

Com­ple­ment Ther­a­peu­tics raised a €72 mil­lion ($79.6 mil­lion) Se­ries A to bankroll a Phase Ib of its AAV gene ther­a­py in ge­o­graph­ic at­ro­phy.

The dis­ease …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times